Anti-epileptic Zebinix receives EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has granted a marketing authorisation for the novel once-daily anti-epileptic Zebinix (eslicarbazepine acetate) as an adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation, Bial and Eisai announced today.
You may also be interested in...
UK pharmacists warned of swine flu vaccination counterfeits
"Unscrupulous traders" are likely to begin selling Tamiflu (oseltamivir) and Relenza (zanamivir) counterfeits if the swine flu situation escalates, the Royal Pharmaceutical Society of Great Britain (RPSBG) has warned. The alert comes in a letter to pharmacists providing information on the swine flu outbreak.
EMEA's PROTECT project accepted for funding
The Innovative Medicines Initiative Joint Undertaking (IMI JU) has agreed to fund the PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).
J&J comes out on top in US reputation study
Johnson & Johnson has reclaimed the top spot in the 10th Annual Harris Interactive Quotient Study, marking it as having the best reputation of the 60 most visible companies in the US.